The benchmark tests on slideability, repositionability, air egress, conformability, application speed, removal speed and finish quality were conducted by three independent applicators at three different skill levels supported by an independent wrap shop. Independent applicators compared seven vehicle wrapping films by major international manufacturers.
The video related to the benchmark test made its debut in the Avery Dennison Graphics Solutions stand at FESPA (The Federation of European Screen Printers Associations) 2013, in London. It is also featured on the Avery Dennison channel in YouTube ��a subsidiary of Google Inc. (GOOG).
The easy-to-apply vehicle wrapping film has proven to be a time and cost saver. It is also available in many colors and finishes. Supreme Wrapping Film can be applied almost 20% faster than other products. This high quality film by Avery permits faster positioning and air-bubble free application as well as long-term removability.
5 Best Industrial Conglomerate Stocks To Own Right Now: Affymax Inc.(AFFY)
Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. It develops peginesatide (Hematide), which has completed Phase III clinical trial for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells. The company has strategic alliance agreements with Takeda Pharmaceutical Company Limited and Nektar Therapeutics AL, Corporation to develop and commercialize Hematide. Affymax, Inc. was founded in 2001 and is based in Palo Alto, California.
Advisors' Opinion:- [By Alpha Exposure]
Investors in Affymax (AFFY) would like you to believe that Omontys will make a miraculous comeback and that Affymax will be a major winner. My belief is that the last AFFY article contained multiple factual errors that when refuted show that the future for Omontys is in fact dire. At the conclusion of this article all doubt should be removed regarding the low likelihood that Omontys returns to market.
- [By Kanak Kanti De]
Amgen needed an Onyx-like acquisition badly. For one, sales of Aranesp and Epogen, its flagship drugs for anemia, are dropping on concerns of safety, and loss of monopoly in 2012 to Affymax (AFFY), which received FDA approval for a rival anemia drug. (Note though, that after Omontys was recalled this year, that problem is resolved for Amgen.) Secondly, four of its top selling products go off patent in 2015.
Top 5 Quality Companies To Watch In Right Now: Biogen Idec Inc(BIIB)
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include the AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin?s lymphoma (NHL); TYSABRI to treat relapsing MS; FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. Biogen Idec Inc.?s products under Phase III consist of PEGylated interferon beta-1a designed to prolong the effects and reduce the dosing frequency of interferon beta-1a; BG-12 for the treatment of MS; Daclizumab, a monoclonal antibody in relapsing MS; Long-lasting factor IX and VIII fusion protein for the treatment of hemophilia B; GA101, a monoclonal antibody for t he treatment of chronic lymphocytic leukemia and NHL; and Dexpramipexole, an orally administered small molecule for the treatment of amyotrophic lateral sclerosis. The company?s Phase I clinical trial products include Anti-LINGO for use in multiple sclerosis, Neublastin for use in neuropathic pain, CD40L for use in systemic lupus erythematosus, ANTI-TWAEK humanized monoclonal antibody for TWEAK, and BIIB037 for use in Alzheimer's disease; and Phase II clinical trial product comprises OCRELIZUMAB, a humanized monoclonal antibody for treating CD20. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; Swedish Orphan Biovitrum AB; Abbott Biotherapeutics Corp; and Vernalis plc. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.
Advisors' Opinion:- [By Polya Lesova]
Biogen Idec Inc. (BIIB) �was the top gainer in the S&P 500. Its shares rallied 13% after the biotech company said Friday that the European Medicines Agency has determined that dimethyl fumarate in its multiple-sclerosis treatment Tecfidera qualifies as a new active substance. This designation will provide 10 years of regulatory exclusivity for the treatment in the European Union.
Top 5 Quality Companies To Watch In Right Now: Spdr Dj Wilshire Small Cap Etf (SLY)
SPDR DJ Wilshire Small Cap ETF (the Fund), formerly streetTRACKS DJ Wilshire Small Cap ETF, seeks to replicate as closely as possible the total return of the Dow Jones Wilshire Small Cap Index (the Index). The Index is a float-adjusted market capitalization weighted index that reflects the shares of securities of the small-cap portion of the Dow Jones Wilshire 5000 Composite Index actually available to investors in the marketplace. The Index includes the components ranked 751 to 2,500 by full market capitalization. The Index consists of common stocks selected for their capitalization. The composition of the Index is reviewed semiannually in March and December. Shares and float factors of the Index are updated on a quarterly basis.
The Fund utilizes a passive or indexing approach and attempts to approximate the investment performance of its Index, by investing in a portfolio of stocks intended to replicate the Index. The Fund�� investment manager is SSgA Funds Management, Inc.
Advisors' Opinion:- [By Will Ashworth]
By the time the dust settled in 2013, small caps won the day (well, year) — the SPDR S&P SmallCap 600 (SLY) had outperformed the SPDR S&P 500 ETF (SPY) by almost 9 percentage points.
- [By Dan Caplinger]
Where the best gains are
The SPDR S&P 500 ETF (NYSEMKT: SPY ) weighs in with 20% gains with its exposure to 500 of the largest companies in the U.S. market. When you step down to mid-cap stocks, though, you'll get even better returns, with the SPDR S&P MidCap 400 ETF (NYSEMKT: MDY ) posting returns of 21% so far in 2013, based on the performance of 400 mid-sized companies domestically. The smallest companies in the market have done better still, as the SPDR S&P SmallCap 600 ETF (NYSEMKT: SLY ) has given investors impressive 24% returns since Jan. 1.
In fact, when you compare returns across stocks of various sizes, you'll get some surprising results:Why are smaller companies outperforming the largest stocks in the market? Historically, smaller stocks have posted better long-term returns than their larger counterparts, with theoreticians pointing to the greater risk involved in small-cap stocks as justifying the higher risk premium that investors should demand in order to hold them over the long run.
Top 5 Quality Companies To Watch In Right Now: Zumiez Inc (ZUMZ)
Zumiez Inc. (Zumiez) is a specialty retailer of action sports related apparel, footwear, equipment and accessories operating under the Zumiez brand name. As of January 28, 2012, the Company operated 434 stores in the United States and 10 stores in Canada. In addition, the Company operates a Website that sells merchandise online. At January 28, 2012, its stores averaged approximately 2,900 square feet. Its apparel offerings include tops, bottoms, outerwear and accessories, such as caps, bags and backpacks, belts, jewelry and sunglasses. Zumiez�� footwear offerings primarily consist of action sports related athletic shoes and sandals. Its equipment offerings, or hardgoods, include skateboards, snowboards and ancillary gear, such as boots and bindings. The Company also offers a selection of other items, such as miscellaneous novelties.
The Company supplements its merchandise assortment with a select offering of private label products across many of its apparel product categories. During the fiscal year ended January 28, 2012 (fiscal 2011), its private label merchandise represented 17.7% of the Company�� net sales. The Company sources its private label merchandise from foreign manufacturers worldwide.
The Company competes with Abercrombie & Fitch, Aeropostale, American Apparel, American Eagle Outfitters, Billabong, CCS, Forever 21, Hollister, Hot Topic, Old Navy, Pacific Sunwear of California, The Buckle, Wet Seal, Tilly��, Urban Outfitters, Big 5 Sporting Goods, Dick�� Sporting Goods, Sport Chalet and The Sports Authority.
Advisors' Opinion:- [By Anna Prior]
Zumiez Inc.'s(ZUMZ) same-store sales rose 2% in February, topping analysts’ expectations, though discounting weighed on margins. Shares edged up 2.3% to $24.37 premarket.
- [By DailyFinance Staff]
Stocks bounced in and out of the plus column before picking a direction on Friday. Unfortunately, the path chosen was down again, though not far. The Dow Jones industrial average (^DJI) extended its losing streak to five days, dropping another 43 points. The Standard & Poor's 500 (^GSPC) fell 5 and the Nasdaq composite (^IXIC) lost 15 points. In all, each of the major averages lost in the neighborhood of a quarter of a percent Friday, and all lost ground for the week. Meanwhile, another once-popular teen retailer took a tumble. Shares of Aeropostale (ARO) tumbled 20 percent after the retailer posted a wider than expected quarterly loss. The stock is now down 60 percent over the past year. But investors were buying some other retailers. Zumiez (ZUMZ), also geared toward teens, rose 2½ percent despite forecasting a loss in the current quarter. A couple of chains geared toward women did well. Ulta Salon (ULTA) gained nearly 6½ percent as earnings topped expectations. Ann (ANN), best known for its Ann Taylor stores, rose 7½ percent. And Coach (COH) gained 2 percent. Other gainers today: Green Mountain (GMCR), maker of Keurig, was up 7 percent, after expanding its deal with Starbucks. Liberty Media (LSTZA) ended its deal to buy those shares of Sirius XM (SIRI) it doesn't already own. Both stocks gained on the news; Liberty up 7 percent, Sirius up 2 percent. And Castlight Health (CSLT) soared nearly 150 percent above its $16 a share IPO price. The company, which helps workers choose healthcare benefits, stands to gain from Obamacare. On the downside: Tesla (TSLA) lost another 3 percent on reports that New York could become the fifth state to block the company from selling direct to consumers. Still, Tesla has a pretty good track record. It's stock has soared more than 500 percent over the past year. Biotechs continued to lose ground. Celgene (CELG) fell 4 percent on a double dose of bad news. British regulators reportedly plan to rejec
No comments:
Post a Comment